Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio reported Q1 EPS losses of $(4.59), missing the consensus estimate of $(4.28) by 7.24%. This represents a 43.54% improvement over the previous year's losses of $(8.13) per share.
May 14, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palisade Bio's Q1 earnings missed estimates, with losses per share of $(4.59) compared to the expected $(4.28), yet showed significant improvement from last year.
Missing the earnings estimate typically results in negative investor sentiment in the short term, leading to potential stock price decline. However, the significant year-over-year improvement in losses might mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100